

# openheart Mortality after admission for heart failure in the UK compared with Japan

Toshiyuki Nagai,<sup>1,2,3</sup> Varun Sundaram,<sup>1,2,4,5</sup> Kieran Rothnie,<sup>1</sup> Jennifer Kathleen Quint,<sup>1</sup> Ahmad Shoaib,<sup>6</sup> Yasuyuki Shiraishi,<sup>7</sup> Shun Kohsaka,<sup>7</sup> Susan Piper,<sup>8</sup> Theresa A McDonagh,<sup>8</sup> Suzanna Marie C Hardman,<sup>9</sup> Ayumi Goda,<sup>10</sup> Atsushi Mizuno,<sup>11</sup> Takashi Kohno,<sup>7</sup> Alan S Rigby,<sup>12</sup> Tsutomu Yoshikawa,<sup>13</sup> Andrew L Clark,<sup>14</sup> Toshihisa Anzai,<sup>2,3</sup> John G F Cleland<sup>14,15</sup>

**To cite:** Nagai T, Sundaram V, Rothnie K, *et al.* Mortality after admission for heart failure in the UK compared with Japan. *Open Heart* 2018;**5**:e000811. doi:10.1136/openhrt-2018-000811

Received 22 February 2018  
Accepted 24 April 2018

## ABSTRACT

**Objective** Mortality amongst patients hospitalised for heart failure (HHF) in Western and Asian countries may differ, but this has not been investigated using individual patient-level data (IPLD). We sought to remedy this through rigorous statistical analysis of HHF registries and variable selection from a systematic literature review.

**Methods and results** IPLD from registries of HHF in Japan (n=3781) and the UK (n=894) were obtained. A systematic literature review identified 23 models for predicting outcome of HHF. Five variables appearing in 10 or more reports were strongly related to prognosis (systolic blood pressure, serum sodium concentration, age, blood urea nitrogen and creatinine). To compare mortality in the UK and Japan, variables were imputed in a propensity model using inverse probability of treatment weighting (IPTW) and IPTW with logistic regression (doubly robust IPTW). Overall, patients in the UK were sicker and in-patient and post-discharge mortalities were greater, suggesting that the threshold for hospital admission was higher. Covariate-adjusted in-hospital mortality was similar in the UK and Japan (IPTW OR: 1.14, 95% CI 0.70 to 1.86), but 180-day postdischarge mortality was substantially higher in the UK (doubly robust IPTW OR: 2.33, 95% CI 1.58 to 3.43).

**Conclusions** Despite robust methods to adjust for differences in patient characteristics and disease severity, HHF patients in the UK have roughly twice the mortality at 180 days compared with those in Japan. Similar analyses should be done using other data sets and in other countries to determine the consistency of these findings and identify factors that might inform healthcare policy and improve outcomes.

## INTRODUCTION

Annually, heart failure (HF) accounts for >80 000 admissions in the UK,<sup>1</sup> >200 000 in Japan<sup>2,3</sup> and >1 million in the USA. Among patients hospitalised for heart failure (HHF), in-hospital mortality is reported to vary from 2.0% to 12.0%<sup>1 3–10</sup> and mortality at 1-year postdischarge from 13.3% to 30.5%.<sup>1 6 8 11</sup>

Differences in mortality estimates for HHF might be due to variations in patient characteristics, severity of HF, comorbidities or

## Key questions

### What is already known about this subject?

- ▶ The outcome of patients hospitalised for heart failure (HHF) is reported to differ markedly among different countries/healthcare systems, despite similarity in international guidelines on management.
- ▶ However, this has not been investigated using individual patient-level data with rigorous statistical analyses.

### What does this study add?

- ▶ We directly compared patient characteristics and outcomes in the UK and Japan.
- ▶ HHF patients in the UK have roughly twice the mortality at 180 days compared with those in Japan even after adjustment by inverse probability of treatment weighting (IPTW) and IPTW with logistic regression (doubly robust IPTW) using covariates strongly associated with mortality identified by a systematic literature review of mortality prediction models.

### How might this impact on clinical practice?

- ▶ In HHF patients, explaining the differences in outcome among countries, cultures and health services independent from disease severity might provide insights that could improve care and outcome and inform healthcare policy decisions.

medical care. Substantial international differences in health service provision may also exist, including criteria for admission, length of stay, care in the community after discharge and treatment. There will also be cultural differences in both the art of medicine and patient attitudes to medical advice, especially between Western and Asian countries. To date, outcomes for HHF in different healthcare systems have been investigated only using aggregate rather than individual patient-level data (IPLD). Comparing the characteristics and outcomes of HHF managed in different cultures might identify differences in practice that could improve care.



© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

### Correspondence to

Dr Toshiyuki Nagai; t.nagai@imperial.ac.uk and Professor John G F Cleland; j.cleland@imperial.ac.uk

Accordingly, we investigated in-hospital and post-discharge mortality using IPLD from registries of HHF in the UK and Japan, adjusting for differences in key prognostic variables identified from a systematic review of published mortality prediction models (MPMs) and using inverse probability of treatment weighting (IPTW) techniques.

## METHODS

### Overall study design

Our main objective was to compare the mortality of HHF patients in the UK and Japan after adjusting for differences in baseline covariates. This involved three steps: (1) first, a systematic review of published MPMs for HHF, identifying the variables predicting mortality and estimating their respective predictive weights; (2) subsequently, the predictors identified by the review were imputed in a propensity model using IPTW to identify patients with similar attributes in the UK and Japan; and (3) finally, outcomes of interest between the weighted groups, including in-hospital, 30-day, 90-day and 180-day post-discharge mortality, were evaluated.

### Systematic review

We searched the Medline/PubMed and Embase databases to identify relevant MPMs. We employed search filters that have been validated and shown to have high sensitivity for identification of clinical prediction models in Medline<sup>12</sup> (online supplementary appendix) to Supplementary file 1 identify 4487 MPMs for HHF. Those with models only for composite outcomes (ie, HF hospitalisation and mortality), those published only as abstracts and duplicate reports were excluded. We also excluded studies when model performance was not quantified using c-statistics or receiver operating characteristic curves. This identified 23 unique MPMs from which information on individual predictor variables could be extracted. For the meta-analyses, studies lacking OR or HR for predictor variables were excluded; 17 studies were finally included in the meta-analysis (figure 1). All studies were reviewed by two independent cardiologists (TN and VS) to ascertain eligibility (see online supplementary table for details on data extraction and reduction, and statistical analysis).

### Study cohorts

Pooled data from two UK and two Japanese registries of HHF were used. In all registries, HHF was defined by hospitalisation with a diagnosis of HF according to the Framingham criteria.

#### UK HHF cohort

1. The Hull and East Yorkshire Hospitals NHS Trust, King's College Hospital NHS Foundation Trust (London) and Whittington Hospital NHS Trust (London) are three large tertiary care hospitals that each provides emergency care to approximately 500 000 people. All three Trusts participate in the England and Wales National Heart Failure Audit.<sup>1</sup>

From 2012 to 2013, 697 HHF patients (307 from Hull; 390 from London) were enrolled. Because it is a National Health Service (NHS) registry, neither specific ethical review nor patient consent is required.

2. The Hull LifeLab is a large, epidemiologically representative, information-rich data set of contemporary diagnosis, treatment and natural history of patients with HF. Its main focus is on out-patient referrals<sup>13</sup>; only patients hospitalised for HF at the time of enrolment between 2010 and 2011 (n=197) were included in this analysis. The registry has ethical approval and patients gave written informed consent.

#### Japanese HHF cohort

1. The WET-HF (WEst Tokyo Heart Failure) registry is an ongoing, prospective observational registry of HHF in five large academic medical centres in metropolitan Tokyo that enrolled 3030 patients between 2005 and 2016.<sup>14</sup>


2. The NaDEF (National cerebral and cardiovascular center for acute DEcompensated heart Failure) registry enrolled 751 patients between 2013 and 2015 from a large centre for cardiovascular medicine located in mid-west Japan.<sup>15</sup>

The study protocols were registered at the Japanese University hospital Medical Information Network (UMIN) Clinical Trial Registration (UMIN000001171 and UMIN000017024, respectively).

### Statistical analysis

The weights of variables predicting mortality were meta-analysed, using fixed-effect and random-effect models. The z-scores (OR/SE and HR/SE) of the OR (for case-control studies) and the HR (for cohort studies) of predictor variables were estimated.<sup>16</sup> Continuous variables were presented as mean±SD. Baseline variables that were significantly different between the two groups were identified using standardised differences. Among these variables, those that were used in more than one MPM (n≥2) and available in both countries were imputed in an IPTW model to develop balanced groups.<sup>17</sup> Balance between the British and Japanese weighted cohorts was evaluated using the standardised differences approach and kernel density plots. For propensity analyses, IPTW was preferred over matching in order to preserve the sample size.<sup>18</sup>

We performed univariable/multivariable logistic regression analyses, IPTW and IPTW with logistic regression (doubly robust IPTW) to compare odds for mortality (in-hospital, 30-day postdischarge, 90-day postdischarge and 180-day postdischarge) in the UK and Japanese cohorts. Additional analysis was performed for postdischarge mortality after controlling for medicines at discharge. All analyses were performed with Stata MP64 V.15.



**Figure 1** Flow diagram of the meta-analyses of published mortality prediction models in HHF patients. AUC, area under the curve; HHF, hospitalised due to heart failure.

## RESULTS

### Systematic review of MPMs

We identified 28 different MPMs from 23 papers published between 2003 and 2017 (online supplementary table). The five variables with the top z-scores were systolic blood pressure (BP), serum sodium concentration, age, blood urea nitrogen (BUN) and serum creatinine; 26 predictor variables appeared in more than one MPM (table 1).

### Cohort baseline characteristics

The baseline characteristics of patients in the UK (n=894) and Japan (n=3781) are shown in table 2. The mean age was similar in UK and Japan, but British patients had more severe HF as evidenced by higher New York Heart Association (NYHA) class, lower systolic BP, lower serum sodium concentrations, higher BUN and serum creatinine concentrations. A higher proportion of Japanese

patients had a left ventricular ejection fraction >45%. The prevalence of ischaemic heart disease and chronic pulmonary obstructive disease (COPD)/asthma was higher among British patients compared with their Japanese counterparts.

### Inverse probability of treatment weighting

After application of IPTW with variables which were used in two or more MPMs and available in both countries (systolic BP, hyponatraemia, age, serum creatinine, COPD/asthma, heart rate, NYHA class, ischaemic heart disease, stroke, left ventricular ejection fraction, atrial fibrillation, diabetes mellitus and sex), there was good balance between British and Japanese patients' characteristics. Standardised differences were <0.1 for most variables other than haemoglobin and medications at discharge. After additional weighting for oral medications at discharge (ACE inhibitor/angiotensin II receptor

**Table 1** Frequency of variables used in the models to predict mortality after hospitalisation for heart failure and their respective weights

Variables	n	OR			HR		
		z-Score	Mean	95% CI	z-Score	Mean	95% CI
Systolic blood pressure	21	42.62	1.17	1.11 to 1.23	51.40	1.18	1.13 to 1.22
Serum sodium	21	43.27	1.15	1.09 to 1.20	17.40	1.20	1.06 to 1.33
Age	21	21.09	1.41	1.28 to 1.54	14.08	1.39	1.19 to 1.58
Blood urea nitrogen	16	27.44	1.57	1.46 to 1.68	39.86	1.29	1.22 to 1.35
Creatinine	14	12.73	1.33	1.12 to 1.53	9.29	1.43	1.13 to 1.73
COPD/asthma	8	10.00	1.53	1.23 to 1.82	12.86	1.44	1.22 to 1.66
Heart rate	7	45.24	1.18	1.13 to 1.23	–	–	–
Albumin	6	34.73	1.57	1.48 to 1.66	11.26	1.42	1.17 to 1.66
Haemoglobin	6	15.11	1.30	1.13 to 1.47	–	–	–
Cancer	6	7.75	2.45	1.83 to 3.07	–	–	–
NYHA class	6	4.57	2.26	1.29 to 3.03	–	–	–
Ischaemic heart disease	4	–	–	–	23.95	1.21	1.11 to 1.30
Dementia	4	20.05	1.85	1.67 to 2.03	–	–	–
Stroke	4	10.31	1.38	1.12 to 1.64	–	–	–
Oxygen saturation	4	2.02	2.05	0.07 to 4.03	–	–	–
Respiratory rate	3	34.59	1.18	1.11 to 1.24	–	–	–
Sex	3	30.59	1.29	1.20 to 1.37	–	–	–
LVEF	3	9.62	1.15	0.91 to 1.38	–	–	–
(N-terminal pro) BNP	3	7.05	1.85	1.33 to 2.36	–	–	–
Transfer by EMS	3	5.74	3.81	2.51 to 5.11	–	–	–
Liver cirrhosis	3	2.20	4.01	0.44 to 7.58	–	–	–
Prior heart failure hospitalisation	3	–	–	–	–	–	–
Potassium	3	–	–	–	–	–	–
Troponin	3	–	–	–	–	–	–
Atrial fibrillation	3	–	–	–	–	–	–
Diabetes mellitus	2	–	–	–	–	–	–

BNP, brain natriuretic peptide; COPD, chronic pulmonary obstructive disease; EMS, emergency medical service; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

blocker, beta blocker, mineralocorticoid receptor antagonist, diuretics and digitalis), balance (standardised difference <0.1) was achieved for all key variables (table 2).

### Mortality before and after IPTW in the UK compared with Japan

Crude analyses showed that mortality was substantially higher in the UK compared with Japan at all time-points (table 3). Unadjusted mortality during hospitalisation was 3.6% in the UK vs 2.2% in Japan, and was, respectively, 3.5% vs 2.7% at 30 days, 9.0% vs 4.4% at 90 days, and 14.7% vs 6.3% at 180 days. Multivariable logistic regression analyses in the unweighted population showed that in-hospital mortality was similar in the UK and Japan, but British patients had a substantially higher mortality by 180 days (table 3). Weighted and doubly robust weighted analyses also showed higher mortality in the UK at 180 days. Because of the low number of events, we did not have the

statistical power to perform doubly robust weighted analyses for in-hospital, 30-day (with and without accounting for medications at discharge) and 90-day mortality (after accounting for medications at discharge) (table 3).

### DISCUSSION

This analysis suggests that HHF patients in the UK have more advanced disease than their Japanese counterparts and a much worse prognosis. After adjusting for differences in patient characteristics using IPTW, in-hospital mortality was similar in the UK and Japan, suggesting that the quality of in-patient care might be similar. However, substantial differences in post-discharge mortality persisted even after adjusting for the prognostic variables that were identified by a systematic literature review and available in both countries. As far as we know, this is the first analysis comparing HHF in Western and Asian

**Table 2** Baseline characteristics in the unweighted and weighted study population

Variable	Unweighted study population			Weighted study population unadjusted for medicines at discharge			Weighted study population adjusted for medicines at discharge			
	% Missing UK/Japan	UK	Japan	Standardised difference	UK	Japan	Standardised difference	UK	Japan	Standardised difference
Patients, n	–	894	3781	–	681	1814	–	605	1373	–
Age, years	0.1/0	73.5 (13.7)	74.5 (13.1)	–0.073	72.5 (14.0)	72.4 (13.9)	0.002	71.7 (14.4)	72.3 (13.7)	–0.040
Male sex, n (%)	0/5.7	555 (62)	2147 (60)	0.038	66%	64%	0.029	65%	65%	0.003
NYHA III or IV, n (%)	2.7/27.2	802 (92)	2259 (82)	0.307	91%	91%	–0.007	91%	91%	0.020
Systolic BP, mm Hg	0.6/12.8	132 (29)	139 (33)	–0.226	134 (29)	133 (31)	0.018	134 (30)	134 (31)	–0.022
Heart rate, bpm	0.7/13.3	91.1 (27.4)	93.6 (29.2)	–0.089	93.2 (27.5)	92.3 (27.6)	0.030	91.6 (27.3)	91.8 (27.0)	–0.008
LVEF ≤45%, n (%)	12.6/18.1	560 (72)	1763 (57)	0.312	75%	73%	0.030	72%	72%	0.008
Comorbidities, n (%)										
IHD	0/0	433 (48)	961 (25)	0.491	40%	41%	–0.008	40%	43%	–0.050
Diabetes mellitus	0.1/0.1	297 (33)	1394 (37)	–0.076	32%	33%	–0.016	31%	32%	–0.029
Hypertension	0.1/0.5	512 (57)	2664 (71)	–0.204	56%	63%	–0.139	57%	63%	–0.127
COPD/asthma	0/15.6	221 (25)	169 (5)	0.565	12%	12%	–0.006	14%	14%	0.006
Atrial fibrillation	0.6/15.4	374 (41)	1550 (48)	–0.129	41%	41%	–0.005	41%	40%	0.026
Stroke	1.3/15.6	88 (10)	532 (17)	–0.198	12%	11%	0.035	10%	10%	0.013
Laboratory data										
Haemoglobin, g/dL	43.7/0.4	12.2 (2.1)	11.9 (2.3)	0.142	12.4 (2.1)	12.2 (2.3)	0.133	12.3 (2.1)	12.2 (2.3)	0.059
Sodium, n (%)	0.1/0.5	137.1 (6.8)	139.2 (5.4)	–0.333	–	–	–	–	–	–
Hyponaatraemia, n (%)	0.1/0.5	264 (30)	558 (15)	0.360	23%	22%	0.018	22%	22%	0.003
BUN, mg/dL	41.7/0.7	32.1 (24.2)	27.7 (17.9)	0.206	29.4 (21.5)	28.3 (18.0)	0.052	28.1 (19.8)	27.9 (19.6)	0.006
Creatinine, mg/dL	0.5/0.5	1.54 (1.24)	1.50 (1.57)	0.028	1.48 (1.07)	1.49 (1.49)	–0.010	1.45 (1.06)	1.50 (1.61)	–0.029
Oral medications at discharge, n (%)										
ACE-I/ARBs	28.1/1.9	682 (76)	2331 (62)	0.465	81%	64%	0.493	84%	82%	0.061
Beta blockers	8.1/1.9	640 (72)	2698 (71)	0.118	80%	77%	0.071	80%	79%	0.021
MRA	22.5/6.9	126 (14)	585 (15)	0.352	52%	38%	0.287	47%	48%	–0.008
Diuretics	6.4/6.5	748 (84)	2487 (66)	0.492	91%	76%	0.415	90%	90%	0.012
Digitalis	24.5/6.4	105 (12)	325 (9)	0.427	26%	9%	0.463	18%	18%	0.003
Length of hospitalisation, days	0.0/8.7	14.9 (13.3)	21.9 (32.3)	–0.284	15.0 (13.8)	24.1 (37.3)	–0.324	14.4 (12.7)	24.1 (33.4)	–0.386

Continuous variables are presented as mean (SD). Categorical variables are presented as number of patients (%).

A standardised difference of 0.1 denotes meaningful imbalance in the variables.

ACE-I, ACE inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; bpm, beats per minute; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.

**Table 3** Outcomes for British and Japanese HHF patients using multiple adjustment techniques

UK vs Japan	Crude			Unweighted			Weighted			Weighted (doubly robust)		
	OR (95% CI)	P values	OR (95% CI)	P values	OR (95% CI)	P values	OR (95% CI)	P values	OR (95% CI)	P values	OR (95% CI)	P values
In-hospital	1.83 (1.28 to 2.63)	0.001	1.10 (0.68 to 1.80)	0.69	1.14 (0.70 to 1.86)	0.59	-	-	-	-	-	-
Unadjusted for medications at discharge												
30-day postdischarge	2.32 (1.60 to 3.37)	<0.001	1.96 (1.18 to 3.24)	0.009	1.92 (1.14 to 3.24)	0.014	-	-	-	-	-	-
90-day postdischarge	2.52 (1.97 to 3.23)	<0.001	1.79 (1.28 to 2.51)	0.001	1.88 (1.33 to 2.64)	<0.001	1.92 (1.34 to 2.75)	<0.001	1.92 (1.34 to 2.75)	<0.001	1.92 (1.34 to 2.75)	<0.001
180-day postdischarge	2.57 (2.09 to 3.17)	<0.001	1.96 (1.49 to 2.60)	<0.001	2.12 (1.59 to 2.81)	<0.001	2.21 (1.63 to 2.99)	<0.001	2.21 (1.63 to 2.99)	<0.001	2.21 (1.63 to 2.99)	<0.001
Adjusted for medications at discharge												
30-day postdischarge	2.32 (1.60 to 3.37)	<0.001	2.71 (1.23 to 5.94)	0.013	2.55 (0.97 to 6.74)	0.059	-	-	-	-	-	-
90-day postdischarge	2.52 (1.97 to 3.23)	<0.001	2.45 (1.59 to 3.79)	<0.001	2.32 (1.46 to 3.68)	<0.001	2.33 (1.58 to 3.43)	<0.001	2.33 (1.58 to 3.43)	<0.001	2.33 (1.58 to 3.43)	<0.001
180-day postdischarge	2.57 (2.09 to 3.17)	<0.001	2.55 (1.83 to 3.55)	<0.001	2.25 (1.58 to 3.22)	<0.001	-	-	-	-	-	-

HHF, hospitalised for heart failure.

countries using IPLD data with doubly robust IPTW. The fact that different methods of adjustment provided similar results suggests that our study has considerable internal validity.

Globally, HHF patients are common, and the numbers are expected to rise as the proportion of older people in the population increases and survival with conditions such as hypertension, ischaemic heart disease and HF itself improves.<sup>219-21</sup> Internationally, guidelines on the management of HF are rather similar but less is known about the differences among patients from different cultures and countries to whom the guidelines are applied. For example, HHF patients in Japan are reported to have a longer length of hospital stay (Japan: 15–21 days; Europe: 7–9 days; USA: 4 days) and lower in-hospital mortality than patients in Europe and the USA (Japan: 2.0%–5.6%; Europe: 5.5%–6.7%; USA: 3.8%–8.9%).<sup>4-7 10 22-24</sup> However, these are crude estimates unadjusted for differences in disease severity. We identified 26 prognostic variables for HHF in a systematic review and used these to adjust for variations in patient characteristics that might have accounted for the differences in mortality. To our knowledge, this is the first systematic review of prognostic variables for HHF; previous systematic reviews focused on chronic HF.<sup>16</sup> Despite risk adjustment, 180-day postdischarge mortality remained substantially higher in the UK than in Japan.

Differences in post-discharge mortality could reflect many factors, including genetics, aetiology of disease, post-discharge care, lifestyle, diet, environment or other unmeasured confounders. For instance, in Japan it is customary for patients with HF to be seen in the outpatient clinic within 4 weeks after discharge, even if the HF is not severe, whereas in the UK patients are more likely to be managed in the community by HF specialist nurses and primary care physicians. The Japanese diet will include more rice and less wheat, more salt, more fish, and less red meat.<sup>25</sup> The weather is warmer in Tokyo than in England. Japanese patients may be more likely to follow medical advice and adhere to their prescribed medication. On the other hand, Japanese doctors generally prescribe much lower doses of medicines than their British colleagues.<sup>26-28</sup> While our analysis estimates the differences in outcomes after adjusting for identified predictor variables, it was not designed to identify the reason for residual disparities.

### Limitations

While both the UK and Japan registries had detailed IPLD, certain important variables that were identified from a systematic literature review, such as respiratory rate, serum albumin, troponin and plasma brain natriuretic peptide levels, and medication compliance, were not consistently available. This study is geographically limited to patients hospitalised in Britain and Japan, and our results may not generalise to other Western or Asian countries. Finally, the study was not designed to identify the reason for residual disparities. However, we believe

that these limitations are outweighed by methodological strengths, including prospective patient enrolment from multiple centres, a systematic review to identify predictor variables and their estimated weights, and the use of multiple adjustment methods including conventional covariate adjustment, IPTW and doubly robust IPTW, all of which yielded similar results.

## CONCLUSION

HHF patients in the UK have a substantially worse prognosis compared with those hospitalised in Japan. Differences persist after accounting for the greater severity of patients admitted with HF in the UK. Explaining the differences in outcome among countries, cultures and health services might provide insights that could improve care and outcome and inform healthcare policy decisions.

## Author affiliations

- <sup>1</sup>National Heart & Lung Institute, Imperial College London, London, UK  
<sup>2</sup>Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan  
<sup>3</sup>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan  
<sup>4</sup>Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA  
<sup>5</sup>Royal Brompton and Harefield Hospitals, London, UK  
<sup>6</sup>Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, University of Keele and Royal Stoke Hospital, Stoke-on-Trent, UK  
<sup>7</sup>Department of Cardiology, Keio University School of Medicine, Tokyo, Japan  
<sup>8</sup>Cardiology Department, King's College Hospital, London, UK  
<sup>9</sup>Clinical and Academic Department of Cardiovascular Medicine, Whittington Hospital, London, UK  
<sup>10</sup>Division of Cardiology, Kyorin University School of Medicine, Tokyo, Japan  
<sup>11</sup>Department of Cardiology, St Luke's International Hospital, Tokyo, Japan  
<sup>12</sup>Department of Statistics, Hull York Medical School, University of Hull, Kingston-upon-Hull, UK  
<sup>13</sup>Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan  
<sup>14</sup>Department of Cardiology, Hull York Medical School, Castle Hill Hospital, Kingston-upon-Hull, UK  
<sup>15</sup>Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow and National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College London, London, UK

**Funding** TN is supported by grants from the Daiichi Sankyo Foundation of Life Science and the Mochida Memorial Foundation for Medical and Pharmaceutical Research. This research was supported by a Butterfield Award for UK–Japan collaboration in Medicine and Health from The Great Britain Sasakawa Foundation.

**Competing interests** JGFC received grants and honoraria from Amgen, Novartis, Medtronic, Philips, Servier and Stealth BioTherapeutics.

**Patient consent** Obtained.

**Ethics approval** The study protocols of both the Japanese registries were approved by the respective institutional review boards.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## REFERENCES

- Cleland JG, McDonagh T, Rigby AS, *et al.* The national heart failure audit for England and Wales 2008–2009. *Heart* 2011;97:876–86.

- Okura Y, Ramadan MM, Ohno Y, *et al.* Impending epidemic: future projection of heart failure in Japan to the year 2055. *Circ J* 2008;72:489–91.
- Yasuda S, Nakao K, Nishimura K, *et al.* The Current Status of Cardiovascular Medicine in Japan – Analysis of a Large Number of Health Records From a Nationwide Claim-Based Database, JROAD-DPC. *Circ J* 2016;80:2327–35.
- Honda S, Nagai T, Sugano Y, *et al.* Prevalence, determinants, and prognostic significance of delirium in patients with acute heart failure. *Int J Cardiol* 2016;222:521–7.
- Fonarow GC, Adams KF, Abraham WT, *et al.* Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. *JAMA* 2005;293:572–80.
- Chioncel O, Mebazaa A, Harjola VP, *et al.* Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2017;19:1242–54.
- Abraham WT, Fonarow GC, Albert NM, *et al.* Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *J Am Coll Cardiol* 2008;52:347–56.
- Lee DS, Austin PC, Rouleau JL, *et al.* Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. *JAMA* 2003;290:2581–7.
- Lee SE, Cho HJ, Lee HY, *et al.* A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry. *Eur J Heart Fail* 2014;16:700–8.
- Sato N, Kajimoto K, Asai K, *et al.* Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. *Am Heart J* 2010;159:949–55.
- Park JJ, Choi DJ, Yoon CH, *et al.* Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry). *Am J Cardiol* 2014;113:511–7.
- Geersing GJ, Bouwmeester W, Zuihthoff P, *et al.* Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews. *PLoS One* 2012;7:e32844.
- Cleland JG, Zhang J, Pellicori P, *et al.* Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure. *JAMA Cardiol* 2016;1:539–47.
- Takei M, Kohsaka S, Shiraishi Y, *et al.* Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction. *Circ Heart Fail* 2015;8:527–32.
- Nagai T, Nishimura K, Honma T, *et al.* Prognostic significance of endogenous erythropoietin in long-term outcome of patients with acute decompensated heart failure. *Eur J Heart Fail* 2016;18:803–13.
- Ouwkerk W, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. *JACC Heart Fail* 2014;2:429–36.
- Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behav Res* 2011;46:399–424.
- Elze MC, Gregson J, Baber U, *et al.* Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. *J Am Coll Cardiol* 2017;69:345–57.
- Roger VL, Weston SA, Redfield MM, *et al.* Trends in heart failure incidence and survival in a community-based population. *JAMA* 2004;292:344–50.
- Levy D, Kenchaiah S, Larson MG, *et al.* Long-term trends in the incidence of and survival with heart failure. *N Engl J Med* 2002;347:1397–402.
- He J, Gu D, Wu X, *et al.* Major causes of death among men and women in China. *N Engl J Med* 2005;353:1124–34.
- Komajda M, Hanon O, Hochadel M, *et al.* Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. *Eur Heart J* 2009;30:478–86.
- Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, *et al.* Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure—A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). *J Cardiol* 2013;62:95–101.
- Makino J, Kohsaka S, Shiraishi Y, *et al.* Application of the United States acute heart failure risk prediction model in Japanese patients; analysis from a contemporary multicenter registry. *Int J Cardiol* 2015;195:323–5.

25. Stamler J, Brown IJ, Daviglius ML, *et al*. Dietary glycine and blood pressure: the International Study on Macro/Micronutrients and Blood Pressure. *Am J Clin Nutr* 2013;98:136–45.
26. Arimura T, Miura S, Morito N, *et al*. Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure. *J Clin Med Res* 2016;8:97–104.
27. Hori M, Sasayama S, Kitabatake A, *et al*. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. *Am Heart J* 2004;147:324–30.
28. Dierckx R, Cleland JG, Parsons S, *et al*. Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period. *JACC Heart Fail* 2015;3:224–30.